Strona główna
  • Zamawiaj do paczkomatu
  • Płać wygodnie
  • Obniżka

Hypertension

A Companion to Brenner and Rector's The Kidney

9780721602585
488,83 zł
439,95 zł Zniżka 48,88 zł Brutto
Najniższa cena w okresie 30 dni przed promocją: 439,95 zł
Ilość
Produkt niedostępny
Nakład wyczerpany (niedostępny u wydawcy)

  Dostawa

Wybierz Paczkomat Inpost, Orlen Paczkę, DPD, Pocztę, email (dla ebooków). Kliknij po więcej

  Płatność

Zapłać szybkim przelewem, kartą płatniczą lub za pobraniem. Kliknij po więcej szczegółów

  Zwroty

Jeżeli jesteś konsumentem możesz zwrócić towar w ciągu 14 dni*. Kliknij po więcej szczegółów

Opis
The revised and updated 2nd Edition provides a logical, practical framework for managing patients with hypertension. Todays leading experts discuss all aspects of the field-from pathophysiology, pharmacological treatments, and lifestyle modifications to secondary hypertension and cardiovascular complications.
Szczegóły produktu
Saunders
33130
9780721602585
9780721602585

Opis

Rok wydania
2005
Numer wydania
2
Oprawa
twarda
Liczba stron
912
Wymiary (mm)
216 x 276
Waga (g)
2472
  • Section 1: Background and History

    1. History of Clinical Hypertension
    2. The National High Blood Pressure Education Program
    3. Epidemiology of Hypertension

    Section 2: Pathophysiology

    4. Pathophysiology of Hypertension
    5. Blood Pressure Genetics
    6. Sympathetic Nervous System in Acute and Chronic Blood Pressure Evaluation
    7. Evironmental and Psychosocial Stress in Hypertension Onset and Progression
    8. Renin
    9. The Genetics of Salt-Related Hypertension
    10. Angiotensin Converting Enzyme: Properties and Function
    11. Angiotensin 1-7
    12. The Angiotensin Receptors: AT1 and AT2
    13. Aldosterone and Mineralocorticoids
    14. What is the Role of Insulin Resistance and Compulsory Hyperinsulinemia in the Pathogenesis and Clinical Course of Patients with Essential Hypertension?
    15. Remodelling of Resistance Arteries in Hypertension
    16. Arterial Stiffness in Hypertension
    17. Endothelium in Hypertension: Nitric Oxide
    18. Endothelium in Hypertension: Endothelin, Prostanoids and Other Mediators.
    19. The Natriuretic Peptides
    20. Vasodilator Peptides: CGRP, Substance P, and Adrenomedullin
    21. Kallikrein - Kinin Systems

    Section 3: TargetOrgan Damage/Cardiovascular Events

    22. The Concept of Total Risk
    23. New Interpretations of Blood Pressure: The Importance ofPulse Pressure
    24. Coronary Atherosclerotic Sequelae of Hypertension
    25. Left Ventricular Hypertrophy, Congestive Heart Failure, and Coronary Flow Reserve Abnormalities in Hypertension
    26. Chronic Renal Insufficiency: Slowing its Progression

    Section 4: Diagnosis

    27. Initial Evaluation and Follow-up Assessment
    28. Prognostic and Diagnostic Value of Ambulatory Blood Pressure Monitoring
    29. White Coat Hypertension

    Section 5: General Consideration

    30. Benefits of Treating Hypertension: The Clinical Trialists Collaborative Group
    31. The Antihypertensive and Lipid-Lowering to Prevent Heart Attack Trial
    32. The LIFE Study
    33. The VALUE Trial
    34. Clinical Outcome Trials of Hypertension with Angiotensin Receptor Blockers
    35. Clinical Trials in Hypertension and Diabetes
    36. ACE Inhibitor Trials: Effects in Hypertension
    37. Critical Assessment of Hypertension Guidelines
    38. Current Prescribing Practices
    39. Calcium Channel Blockers: Controversies, Lessons and Outcomes
    40. Nursing Clinics in the Management of Hypertension
    41. Community Outreach
    42. Medication Adherence for Antihypertensive Therapy

    Section 6: Diet and Nutrition

    43. Micronutrients
    44. Dietary Approaches to Hypertension Management: The DASH Studies
    45. Obesity and Hypertension: Effects on the Cardiovascular and Renal Systems
    46. Alcohol and Hypertension
    47. Obesity in Hypertension: The Role of Diet and Drugs
    48. Exercise and Hypertension

    Section 7:Pharmacological Treatment

    49. Initial Choices in the Treatment of Hypertension
    50. Pharmacokinetics of Antihypertensive Drugs
    51.Fixed Combination Antihypertensive Therapy
    52. Chronotherapeutics in the Treatment of Hypertension

    Section 8: Comorbid Conditions and Special Populations in Hypertension

    53. Diabetes Mellitis and the Cardiovascular/Metabolic Syndrome: Reducing Cardiovascular and Renal Events
    54. Hypertension in Patients on Renal Replacement Therapy
    55. Ischemic Heart Disease in Hypertension
    56. Hypertension in the Elderly
    57. Management of Hypertension in Black Populations
    58. Hypertension in Pregnancy
    59. Hypertension in Children
    60. Resistant Hypertension
    61. Orthostatic Hypotension and Autonomic Dysfunction Syndromes

    Section 9: Individual Drug Classes

    62. Diuretics: Mechanisms of Action
    63. Beta-Adrenergic Blockers
    64. Alpha-Adrenoceptor Blockers
    65. Angiotensin Converting Enzyme Inhibitors
    66. Calcium Antagonists
    67. Angiotensin II Receptor Antagonists
    68. Direct Acting Smooth Muscle Vasodilators and Adrenergic Inhibitors
    69. Endothelin Antagonists
    70. Mineralocorticoid Receptor Antagonists
    71. Vasopeptidase Inhibitors
    72. Renin Inhibitors

    Section 10: Secondary Hypertension

    73. Obstructive Sleep Apnea and Hypertension
    74. Renovascular Hypertension: Diagnosis and Treatment
    75. Adrenal Cortex Hypertension
    76. Pheochromocytoma: Detection and Management
    77. Anesthesia and Hypertension
    78. Management of Hypertensive Emergencies and Urgencies
    79. Aggressive Blood Pressure Targets: Developing Effective Algorithms
Komentarze (0)

  • Często kupowane razem

    Brak dostępnych produktów